IL315617A - Preparations with improved bioavailability of drugs and their uses - Google Patents
Preparations with improved bioavailability of drugs and their usesInfo
- Publication number
- IL315617A IL315617A IL315617A IL31561724A IL315617A IL 315617 A IL315617 A IL 315617A IL 315617 A IL315617 A IL 315617A IL 31561724 A IL31561724 A IL 31561724A IL 315617 A IL315617 A IL 315617A
- Authority
- IL
- Israel
- Prior art keywords
- therapeutics
- compositions
- improved bioavailability
- bioavailability
- improved
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263269330P | 2022-03-14 | 2022-03-14 | |
| PCT/EP2022/058180 WO2022207580A2 (en) | 2021-03-27 | 2022-03-28 | Compositions having improved bioavailability of therapeutics |
| PCT/EP2023/056506 WO2023174948A2 (en) | 2022-03-14 | 2023-03-14 | Compositions having improved bioavailability of therapeutics and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL315617A true IL315617A (en) | 2024-11-01 |
Family
ID=85571360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL315617A IL315617A (en) | 2022-03-14 | 2023-03-14 | Preparations with improved bioavailability of drugs and their uses |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP4493151A2 (de) |
| JP (1) | JP2025509680A (de) |
| AU (1) | AU2023233811A1 (de) |
| CA (1) | CA3245873A1 (de) |
| IL (1) | IL315617A (de) |
| WO (1) | WO2023174948A2 (de) |
| ZA (1) | ZA202407659B (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025072929A1 (en) * | 2023-09-28 | 2025-04-03 | The Regents Of The University Of California | Methods and compositions of treating age-related conditions |
| WO2025093572A1 (en) * | 2023-10-29 | 2025-05-08 | TRx Biosciences Limited | Solid dispersion compositions and uses thereof |
| WO2026053168A1 (en) * | 2024-09-06 | 2026-03-12 | Graviton Bioscience Bv | Amorphous forms of a rock2 inhibitor and formulations thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5082667A (en) * | 1988-06-07 | 1992-01-21 | Abbott Laboratories | Solid pharmaceutical dosage in tablet triturate form and method of producing same |
| US5885486A (en) * | 1993-03-05 | 1999-03-23 | Pharmaciaand Upjohn Ab | Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof |
| US20020028813A1 (en) * | 1997-09-03 | 2002-03-07 | Paul F. Jackson | Thioalkyl compounds, methods, and compositions for inhibiting parp activity |
| US6063768A (en) | 1997-09-04 | 2000-05-16 | First; Eric R. | Application of botulinum toxin to the management of neurogenic inflammatory disorders |
| US20060138059A1 (en) | 2004-12-28 | 2006-06-29 | Vair Larry L Jr | Corona-treated polypropylene liquid filtration media |
| EP2220073B1 (de) * | 2007-11-15 | 2014-09-03 | MSD Italia S.r.l. | Pyridazinonderivate als parp-inhibitoren |
| ME02640B (de) * | 2008-10-07 | 2017-06-20 | Kudos Pharm Ltd | Pharmazeutische formulierung 514 |
| CN102307576A (zh) * | 2008-12-15 | 2012-01-04 | 班纳制药公司 | 用于增强水不溶性活性剂的释放和吸收的方法 |
| CN101507707B (zh) * | 2009-04-08 | 2011-01-19 | 邓菊娟 | 一种盐酸法舒地尔脂微球制剂及其制备方法 |
| CN101926757B (zh) * | 2010-09-01 | 2013-01-02 | 北京大学 | 一种难溶性药物的液体组合物及其制备方法 |
| CN102813639B (zh) * | 2011-06-08 | 2014-04-30 | 中国疾病预防控制中心寄生虫病预防控制所 | 甲苯达唑软胶囊剂 |
| CA2865040C (en) * | 2012-02-21 | 2020-07-14 | Merck Patent Gmbh | Cyclic diaminopyrimidine derivatives |
| EA201690608A1 (ru) * | 2013-12-04 | 2016-12-30 | Джилид Сайэнс, Инк. | Способы лечения раковых заболеваний |
| US11629118B2 (en) * | 2017-03-03 | 2023-04-18 | Inspirna, Inc. | Formulations with improved stability |
| AU2019363244B2 (en) * | 2018-10-15 | 2024-10-03 | Cipla Limited | Pharmaceutical formulation |
| WO2020217235A1 (en) * | 2019-04-24 | 2020-10-29 | Aizant Drug Research Solutions Private Limited | Solid dosage form of dasatinib |
| CN113546045B (zh) * | 2021-08-18 | 2022-11-11 | 浙江大学 | 恢复肿瘤微环境失活树突状细胞功能的纳米制剂及应用 |
-
2023
- 2023-03-14 JP JP2024555003A patent/JP2025509680A/ja active Pending
- 2023-03-14 AU AU2023233811A patent/AU2023233811A1/en active Pending
- 2023-03-14 WO PCT/EP2023/056506 patent/WO2023174948A2/en not_active Ceased
- 2023-03-14 CA CA3245873A patent/CA3245873A1/en active Pending
- 2023-03-14 IL IL315617A patent/IL315617A/en unknown
- 2023-03-14 EP EP23710760.2A patent/EP4493151A2/de active Pending
-
2024
- 2024-10-09 ZA ZA2024/07659A patent/ZA202407659B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023174948A3 (en) | 2023-10-26 |
| CA3245873A1 (en) | 2023-09-21 |
| AU2023233811A1 (en) | 2024-09-19 |
| EP4493151A2 (de) | 2025-01-22 |
| JP2025509680A (ja) | 2025-04-11 |
| ZA202407659B (en) | 2026-01-28 |
| WO2023174948A2 (en) | 2023-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL315617A (en) | Preparations with improved bioavailability of drugs and their uses | |
| IL306029A (en) | Preparations with improved bioavailability of medical treatments | |
| IL310530A (en) | Stabilized compositions of radionuclides and their uses | |
| PL4090332T3 (pl) | Kompozycje podstawionych pirazolopirymidyn i ich zastosowania | |
| IL304159A (en) | A preparation containing bl-8040 | |
| IL318328A (en) | Compositions comprising multi-agonist peptides and methods for making and using them | |
| IL325330A (en) | Solid forms of posiphen d-tartrate | |
| GB2622995B (en) | CAS13-based compositions and methods of use thereof | |
| IL287137A (en) | Preparations and methods for administration of healing substances | |
| IL315862A (en) | Angiotensinogen modulators and methods of using them | |
| IL316049A (en) | Musuntuzumab pharmaceutical preparations and methods of use | |
| GB202012765D0 (en) | Compositions and methods of production thereof | |
| GB202411091D0 (en) | Compositions and uses | |
| GB202215065D0 (en) | Compositions and uses thereof | |
| GB202209335D0 (en) | Compositions and uses thereof | |
| GB202406865D0 (en) | Novel compounds and therapeutics uses thereof | |
| GB202311665D0 (en) | Modification of composition | |
| GB201919385D0 (en) | Compositions and methods of manufacture | |
| IL319457A (en) | Staurosporine analog compounds and uses thereof | |
| IL316654A (en) | Preparation and uses of 7-azaindenoisoquinolines | |
| GB202405768D0 (en) | Compositions and uses of oligo-chromopeptides and methods of making | |
| GB202312354D0 (en) | Novel compounds, compositions and therapeutics uses thereof | |
| GB202215064D0 (en) | Compositions and uses thereof | |
| GB202213726D0 (en) | Compositions and uses thereof | |
| GB202210107D0 (en) | Compositions and uses thereof |